Pulmonary vein isolation by visually guided laser balloon ablation: single-center 5-year follow-up results.
Ablation
Atrial fibrillation
Laser balloon
Long-term follow-up
Pulmonary vein isolation
Journal
Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing
ISSN: 1572-8595
Titre abrégé: J Interv Card Electrophysiol
Pays: Netherlands
ID NLM: 9708966
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
received:
31
07
2022
accepted:
03
04
2023
medline:
5
12
2023
pubmed:
15
4
2023
entrez:
14
4
2023
Statut:
ppublish
Résumé
Visually guided laser balloon (VGLB) ablation is a balloon-based treatment for atrial fibrillation (AF) that uses a titratable laser energy source to perform pulmonary vein isolation (PVI), allowing for real-time visualization of target tissue and ablation lesions through an endoscopic camera. Few long-term data on this technique are currently available. This report presents acute efficacy, procedural data, complication rates, and long-term AF-free survival up to 5 years post-ablation. In this single-center, retrospective, observational report, 152 patients (72.4% male, mean age 60.6 ± 9.7 years, 62.5% paroxysmal AF, 598 pulmonary veins in total) treated with the first-generation VGLB system between 2014 and 2016 were included for analysis. AF ablation consisted of PVI only. Acute PVI was achieved in 98.2% of veins, with first-pass isolation in 92.5%. Procedure duration of 129 min [IQR 113-150], fluoroscopy time of 15 min [IQR 11-20], and dose area product of 5016 mGy·cm First-generation VGLB ablation demonstrated high acute isolation rates, reasonable procedure times and low complication rates. Long-term freedom from AF was 78.8% for paroxysmal AF and 65.3% for persistent AF, performing PVI only.
Sections du résumé
BACKGROUND
BACKGROUND
Visually guided laser balloon (VGLB) ablation is a balloon-based treatment for atrial fibrillation (AF) that uses a titratable laser energy source to perform pulmonary vein isolation (PVI), allowing for real-time visualization of target tissue and ablation lesions through an endoscopic camera. Few long-term data on this technique are currently available. This report presents acute efficacy, procedural data, complication rates, and long-term AF-free survival up to 5 years post-ablation.
METHODS
METHODS
In this single-center, retrospective, observational report, 152 patients (72.4% male, mean age 60.6 ± 9.7 years, 62.5% paroxysmal AF, 598 pulmonary veins in total) treated with the first-generation VGLB system between 2014 and 2016 were included for analysis. AF ablation consisted of PVI only.
RESULTS
RESULTS
Acute PVI was achieved in 98.2% of veins, with first-pass isolation in 92.5%. Procedure duration of 129 min [IQR 113-150], fluoroscopy time of 15 min [IQR 11-20], and dose area product of 5016 mGy·cm
CONCLUSIONS
CONCLUSIONS
First-generation VGLB ablation demonstrated high acute isolation rates, reasonable procedure times and low complication rates. Long-term freedom from AF was 78.8% for paroxysmal AF and 65.3% for persistent AF, performing PVI only.
Identifiants
pubmed: 37059926
doi: 10.1007/s10840-023-01544-6
pii: 10.1007/s10840-023-01544-6
pmc: PMC10694101
doi:
Types de publication
Observational Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2081-2089Informations de copyright
© 2023. The Author(s).
Références
Clin Res Cardiol. 2018 May;107(5):405-412
pubmed: 29285621
N Engl J Med. 2015 May 7;372(19):1812-22
pubmed: 25946280
Circ Arrhythm Electrophysiol. 2017 Jul;10(7):
pubmed: 28687670
J Interv Card Electrophysiol. 2016 Dec;47(3):341-348
pubmed: 27475949
Europace. 2020 May 1;22(5):748-760
pubmed: 32227238
J Interv Card Electrophysiol. 2021 Oct;62(1):199-211
pubmed: 33011920
J Cardiovasc Electrophysiol. 2014 Dec;25(12):1293-8
pubmed: 25065945
J Interv Card Electrophysiol. 2019 Apr;54(3):237-245
pubmed: 30343439
J Cardiovasc Electrophysiol. 2013 Sep;24(9):987-94
pubmed: 23800359
BMC Cardiovasc Disord. 2017 May 25;17(1):135
pubmed: 28545407
N Engl J Med. 2018 Feb 01;378(5):417-427
pubmed: 29385358
J Cardiovasc Electrophysiol. 2017 Sep;28(9):984-993
pubmed: 28635046
JAMA. 2019 Apr 2;321(13):1261-1274
pubmed: 30874766
Europace. 2013 May;15(5):685-9
pubmed: 23129544
J Am Coll Cardiol. 2015 Sep 22;66(12):1350-60
pubmed: 26383722
Europace. 2014 Dec;16(12):1746-51
pubmed: 25031237
Int J Cardiol Heart Vasc. 2020 Jul 03;29:100576
pubmed: 32642555
JAMA. 2014 Feb 19;311(7):692-700
pubmed: 24549549
Int J Cardiol. 2020 Aug 1;312:73-80
pubmed: 32241572
Europace. 2018 Jan 1;20(1):157-208
pubmed: 29016841
J Cardiovasc Electrophysiol. 2012 Jun;23(6):576-82
pubmed: 22229948
J Cardiovasc Electrophysiol. 2013 Jan;24(1):7-13
pubmed: 22966825
Circulation. 2010 Dec 7;122(23):2368-77
pubmed: 21098450
Circ Arrhythm Electrophysiol. 2013 Jun;6(3):467-72
pubmed: 23559674
N Engl J Med. 1998 Sep 3;339(10):659-66
pubmed: 9725923
Europace. 2016 Apr;18(4):538-42
pubmed: 26316147
Circ Arrhythm Electrophysiol. 2017 Dec;10(12):
pubmed: 29217521